Aspen to Buy Glaxo Drugs for $372 Million as Deal Spree Goes On

  • South African company signs second deal to add anesthetics
  • Aspen, Glaxo also agree to end sub-Saharan Africa partnership

Aspen Pharmacare Holdings Ltd. agreed to buy a portfolio of anesthetic medicines from GlaxoSmithKline Plc for as much as 280 million pounds ($372 million) as Africa’s biggest maker of generic drugs continues a spending spree.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.